We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

2 hedge funds and large institutions have $10 invested in Aridis Pharmaceuticals Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

99% less capital invested

Capital invested by funds: $1.44K → $10 (-$1.43K)

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCWM
Bartlett & Co Wealth Management
Ohio
+$10

Top Sellers

Rank Fund Capital Flow
1
WA
Wealth Architects
California
-$1.44K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCWM
1
Bartlett & Co Wealth Management
Ohio
$10 +$10 +150 New
WA
2
Wealth Architects
California
– -$1.44K -14,077 Closed

ARDS Hedge Fund Activity: Q4 2023 in Review

2 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2023, worth a combined $10 — down 99% from $1.44K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ARDS positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Bartlett & Co Wealth Management, opening a new position worth an estimated $10. The largest seller was Wealth Architects, exiting entirely with an estimated $1.44K sold.

  • 2 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2023, up from 1 in Q3 2023.
  • Funds reported $10 of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2023, down 99% quarter-over-quarter.
  • 2 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of +1 holder.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2023 was Bartlett & Co Wealth Management, an estimated $10 added.
  • The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2023 was Wealth Architects, an estimated $1.44K sold.

Based on aggregated 13F filings for Q4 2023.